• Rapid Diagnostic Tests: These were proprietary, rapid diagnostic tests designed for various medical conditions.
• Outpatient Medical Services: The company provided outpatient management for rehabilitation and other medical services for specific patient populations.

As Advanced Biomed (symbol: ADVB) is a hypothetical public company, specific customer data is not available from real-world public filings or reports. However, based on the typical business models of companies in the "Advanced Biomed" sector (which implies biotechnology, pharmaceuticals, or advanced medical devices), it is highly probable that it primarily sells to other companies and institutions (B2B) rather than directly to individual consumers.

Assuming a B2B model for Advanced Biomed, its major customers would likely fall into categories such as:

• Pharmaceutical Wholesalers and Distributors: These companies purchase biopharmaceutical products, medical devices, and diagnostic tools in bulk from manufacturers like Advanced Biomed for distribution to pharmacies, hospitals, and clinics across large geographical areas.

  Illustrative Public Company Examples:

  • McKesson Corporation (MCK)
  • AmerisourceBergen Corporation (ABC)
  • Cardinal Health, Inc. (CAH)

• Hospital Systems and Integrated Healthcare Networks: Direct purchasers of specialized medical devices, advanced diagnostic kits, and biopharmaceutical products for patient care within their extensive networks of hospitals, clinics, and outpatient facilities.

  Illustrative Examples (many are private or non-profit entities, representing major customer types):

  • Mayo Clinic (Non-profit)
  • Kaiser Permanente (Non-profit)
  • Ascension (Non-profit)

• Other Biotechnology and Pharmaceutical Companies: Advanced Biomed might engage in licensing agreements, supply specialized raw materials/biologics, or provide contract research/manufacturing services to larger pharmaceutical firms for their own product development or production pipelines.

  Illustrative Public Company Examples:

  • Johnson & Johnson (JNJ)
  • Pfizer Inc. (PFE)
  • Thermo Fisher Scientific Inc. (TMO)

null

Dr. Yi Lu, Chairman of the Board and Chief Executive Officer

Dr. Yi Lu was appointed CEO in March 2024 and has served as Chairman since November 2022. He co-founded Advanced Biomed in 2014, where he has also been the Chairman and Chief Science Officer of Advanced Biomed Taiwan since June 2014. Dr. Lu's extensive career includes serving as Chairman of HFC Semiconductor from January 2020 to October 2022. He previously held the position of Chairman at Nextchip Semiconductor Corporation, a semiconductor foundry, from February 2016 to December 2019, where he spearheaded a significant RMB20 billion investment to establish the first 12-inch integrated circuit production line in Anhui Province. From 2004 to 2007, he was a senior executive at Cypress Semiconductor. Notably, Dr. Lu was the founder, Chairman, and CEO of Cascade Semiconductor from 2001 to 2004, a company that was subsequently acquired by Cypress Semiconductor Corporation. He holds a Ph.D. from the University of Florida, obtained in 1994, and possesses considerable experience in entrepreneurship, technology management, market management, and operations.

Mingze Yin, Chief Financial Officer and Principal Accounting Officer

Mingze Yin serves as Advanced Biomed's Chief Financial Officer and Principal Accounting Officer. His reported annual compensation is US$161,740.

Dr. Steven I-Fang Cheng, Chief Technology Officer and Director

Dr. Steven I-Fang Cheng has been the Chief Technology Officer since November 2022 and a Director since May 2025. He co-founded Advanced Biomed Taiwan in 2014, also serving as its CTO. Since 2013, Dr. Cheng has been an associate research fellow (Principal Investigator) at TSRI. His professional expertise encompasses biomicrofluidics, biosensors, cancer diagnosis and infectious detection, micro/nano fabrication technology, on-chip drug screening, electrokinetics/electrical analysis, and their biomedical applications, as well as patent design and implementation.

The key risks to Advanced Biomed (symbol: ADVB) are primarily related to its financial health, the inherent challenges of the healthcare sector, and market volatility.

1. Financial Health and Going Concern: Advanced Biomed faces significant financial challenges, including a lack of profitability and operational inefficiencies. The company has reported 0% revenue growth over the past three years, an EPS of -0.16, and zero operating, net, and gross margins. Furthermore, ADVB reported a consolidated net loss of over $3.2 million for the year and substantial net cash used in operating activities, leading management to express "substantial doubt about going concern." The company's continued operations are dependent on its ability to raise additional capital and rely on future operations. While an initial public offering in March 2025 raised $6.56 million and an equity line of credit provides access to up to $25 million, ongoing losses and reliance on external financing remain a critical risk.
2. Regulatory and Technological Risks in the Healthcare Sector: Operating within the healthcare sector, Advanced Biomed is inherently exposed to risks associated with regulatory changes and rapid technological advancements. The broader healthcare and life sciences industries frequently grapple with stringent regulatory compliance, complexities in research and development processes, and intense market competition. These factors can significantly impact business operations and the successful commercialization of new products.
3. Market Volatility and Low Institutional Interest: ADVB's stock has demonstrated considerable price volatility, with recent daily movements exceeding 10% and an average weekly volatility of nearly 14%. This volatility is potentially exacerbated by relatively low institutional ownership, which stands at 0.61%. Significant negative market reactions have been observed following company news, with one instance resulting in a 17.18% decline in stock value. Such fluctuations suggest the stock may be sensitive to sentiment shifts and potentially algorithmic or retail-driven selling pressure, common in lower-capitalization stocks.

null

Advanced Biomed (ADVB) is expected to drive future revenue growth over the next 2-3 years through the following key initiatives:

1. Commercialization of NMPA-Cleared Products: Advanced Biomed has received clearance from the National Medical Products Administration (NMPA) for its A+Pre and AC-1000 products. The successful commercial launch and subsequent sales of these diagnostic tools in existing markets are anticipated to be a primary revenue driver.
2. Growth of Recently Launched A+PerfusC™ Platform: The company announced the launch of its A+PerfusC™ – Integrated Perfusion 3D Cell Culture Platform in September 2025. The increasing adoption and sales of this platform for precision medicine and drug discovery are expected to contribute significantly to future revenue.
3. Launch of New Diagnostic Products Following Regulatory Approvals: Advanced Biomed has several products, including A+SCDrop, A+CellScan, and A+LCGuard, currently in various stages of the registration application process. A+LCGuard is slated to begin clinical trials in November 2025, with completion expected within six months. The successful regulatory approval and subsequent market introduction of these pipeline products are critical for revenue generation.
4. Expansion into North American and European Markets: The company has strategic plans for geographical expansion into North America and Europe. This involves establishing operational centers and recruiting personnel in the United States by the end of 2025, followed by product registration, testing, and localized production in these new markets, with Europe targeted for 2026. This expansion is expected to open significant new revenue streams.

[1] Share Repurchases

• Advanced Biomed Inc. has not reported any dollar amount of share repurchases over the last 3-5 years, with the last 12-month buyback per share being $0.0.

[2] Share Issuance

• Advanced Biomed Inc. completed its Initial Public Offering (IPO) on March 7, 2025, raising $6.56 million in gross proceeds through the sale of 1,640,000 common stock shares at $4.00 per share.
• The company granted the underwriter a 45-day option to purchase up to an additional 246,000 shares of common stock.
• Advanced Biomed secured a $25 million equity line of credit (ELOC) agreement with Helena Global Investment Opportunities I on June 6, 2025, which allows for the potential issuance of up to 40 million shares of common stock, with the actual number dependent on market price.

[3] Inbound Investments

• On June 6, 2025, Advanced Biomed Inc. secured a $25 million equity line of credit from Helena Global Investment Opportunities I Ltd. This agreement provides flexible access to growth capital for research and development and working capital.

[4] Outbound Investments

• There is no information available regarding significant outbound investments or acquisitions made by Advanced Biomed (ADVB) in other companies over the last 3-5 years.

[5] Capital Expenditures

• Capital expenditures for Advanced Biomed were approximately $0.06 million in the fiscal year ending March 2025, $0.07 million in the fiscal year ending March 2024, and $0.21 million in the fiscal year ending March 2023.
• Proceeds from the IPO, which closed in March 2025, are allocated to fund IVD clinical research, chip design and development, and facility upgrades.
• Funds from the $25 million equity line of credit are intended to support research and development (R&D) and working capital.